medroxyprogesterone acetate
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | DEPO-SUBQ PROVERA 104 | — | 2020-12-04 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | DEPO-PROVERA | — | 2010-10-15 – 2011-07-28 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | PROVERA | — | 1979-06-06 – 1998-08-04 | fda.gov ↗ |
| Approved | US (FDA) | PROVERA | — | 1959-06-18 | fda.gov ↗ |
Trials 98 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04423068 | Dec 2020 → Apr 2022 | pregnancy disorder | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| Phase 0 | NCT03197961 | Nov 2017 → Apr 2018 | HIV infectious disease | Sharon Achilles | Completed | No outcome recorded |
| Phase 113 trials | ||||||
| Phase 1 | NCT04893798 | Sep 2021 → Jul 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04682353 | Dec 2020 → Jul 2022 | — | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03700658 | Jan 2019 → Oct 2020 | — | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03443089 | Mar → Apr 2017 | — | Galeno Desenvolvimento de Pesquisas Clínicas | Completed | No outcome recorded |
| Phase 1 | NCT02732418 | Dec 2016 → May 2018 | — | FHI 360 | Completed | No outcome recorded |
| Phase 1 | NCT02817464 | Oct 2016 → Dec 2018 | pregnancy disorder | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02456584 | Sep 2015 → Aug 2018 | — | FHI 360 | Completed | No outcome recorded |
| Phase 1 | NCT02272647 | Dec 2014 → Dec 2016 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01265017 | Jul 2012 → Jun 2020 | type 1 diabetes mellitus | Sansum Diabetes Research Institute | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT01231451 | Dec 2010 → Jun 2011 | HIV infectious disease | St Stephens Aids Trust | Withdrawn | No outcome recorded |
| Phase 1 | NCT00630435 | Feb → Jun 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00401219 | Nov 2006 → Feb 2007 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00044837 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03264781 | Aug 2016 → Dec 2017 | uterine disorder | Chulalongkorn University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01699022 | Jun 2010 → Jul 2011 | — | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 214 trials · 1 missed | ||||||
| Phase 2 | NCT07377734 | Jan 2026 → Dec 2027 expected | atypical endometrial hyperplasia, endometrial cancer | Wang Jianliu | Recruiting | No outcome recorded |
| Phase 2 | NCT06979596 | Aug 2025 → Nov 2027 expected | cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT06914297 | Apr 2025 → Oct 2027 expected | endometrial cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05675787 | Jan 2023 → Aug 2025 overdue | atypical endometrial hyperplasia, endometrial carcinoma | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04997811 | Dec 2021 → Jan 2025 | myelodysplastic syndrome | Prof. Janet Dunn | Unknown | No outcome recorded |
| Phase 2 | NCT03567655 | Jul 2018 → Oct 2022 | endometrial cancer | Asan Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02412436 | Nov 2015 → Jun 2017 | HIV infectious disease, tuberculosis | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT02335203 | Feb 2015 → Mar 2016 | complex endometrial hyperplasia, endometrial endometrioid adenocarcinoma | Women and Infants Hospital of Rhode Island | Unknown | No outcome recorded |
| Phase 2 | NCT01296152 | May 2011 → Oct 2012 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT00577122 | Jul 2007 → Dec 2011 | estrogen-receptor negative breast cancer, female breast carcinoma, progesterone-receptor negative breast cancer | Indiana University | Completed | No outcome recorded |
| Phase 2 | NCT00370019 | Aug 2006 → Dec 2011 | primary ovarian failure | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Withdrawn | No outcome recorded |
| Phase 2 | NCT00064025 | Apr 2004 → Sep 2010 | endometrial adenosquamous carcinoma, endometrioid adenocarcinoma, endometrium adenocarcinoma, uterine corpus cancer | Gynecologic Oncology Group | Completed | Missed primary |
| Phase 2 | NCT00033358 | Feb 2002 → Oct 2007 | endometrial cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00003179 | Nov 1998 → Feb 2006 | endometrial cancer | Gynecologic Oncology Group | Terminated | No outcome recorded |
| Phase 2/37 trials · 1 met primary | ||||||
| Phase 2/3 | NCT07319429 | Jan 2026 → Dec 2027 expected | endometrial cancer, infertility disorder | Fudan University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05973253 | Apr → Jun 2023 | — | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT05565573 | Nov 2022 → Jul 2024 | — | Hua Li | Unknown | No outcome recorded |
| Phase 2/3 | NCT03463252 | Apr 2018 → Dec 2025 overdue | atypical endometrial hyperplasia, endometrial cancer | West China Second University Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT00083824 | Mar 2004 → Feb 2007 | coronary atherosclerosis | Tufts University | Completed | No outcome recorded |
| Phase 2/3 | NCT00088153 | Jul 2003 → Feb 2011 | anorexia nervosa | Massachusetts General Hospital | Completed | Met primary |
| Phase 2/3 | NCT00066157 | Sep 2001 → Dec 2007 | Alzheimer disease | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 324 trials · 3 met primary · 2 missed | ||||||
| Phase 3 | NCT07831902 | Jun 2026 → Dec 2030 expected | endometrial cancer | University College, London | Recruiting | No outcome recorded |
| Phase 3 | NCT05326087 | Jun 2026 → Dec 2027 expected | polycystic ovary syndrome | ShangHai Ji Ai Genetics & IVF Institute | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07124195 | Aug 2025 → Oct 2026 expected | cancer, chemotherapy-induced toxicity | The First Affiliated Hospital of Xinxiang Medical College | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06145438 | Sep 2023 → Aug 2024 | ovarian endometriosis | Universitas Diponegoro | Completed | No outcome recorded |
| Phase 3 | NCT04414761 | Jun 2020 → Oct 2022 | — | ShangHai Ji Ai Genetics & IVF Institute | Completed | Missed primary |
| Phase 3 | NCT03675139 | Feb 2019 → May 2022 | endometrial hyperplasia without atypia | Xiaojun Chen | Completed | No outcome recorded |
| Phase 3 | NCT03300960 | Oct 2017 → Jun 2019 | infertility disorder | Instituto Valenciano de Infertilidad, IVI VALENCIA | Completed | No outcome recorded |
| Phase 3 | NCT03154125 | Sep 2017 → May 2020 | — | FHI 360 | Completed | No outcome recorded |
| Phase 3 | NCT02922348 | Mar 2016 → Dec 2018 | primary ovarian failure | University of Pennsylvania | Withdrawn | No outcome recorded |
| Phase 3 | NCT02449161 | Aug 2015 → May 2021 | menstrual disorder | Guy Waddell | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT01461824 | Sep 2011 → Apr 2015 | disease of bone structure, uterine disorder | Nationwide Children's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01011751 | Apr 2004 → Dec 2007 | prostate adenocarcinoma | Takeda | Completed | Met primary |
| Phase 3 | NCT00030914 | Apr 2002 → Feb 2006 | — | Alliance for Clinical Trials in Oncology | Completed | Met primary |
| Phase 3 | NCT00026286 | Nov 2000 → Aug 2002 | breast cancer | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00291369 | Dec 1999 → Feb 2005 | renal cell carcinoma | Centre Leon Berard | Completed | No outcome recorded |
| Phase 3 | NCT00000430 | Oct 1999 → Sep 2004 | osteoporosis | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Terminated | No outcome recorded |
| Phase 3 | NCT00002920 | Mar 1997 → Dec 2006 | breast cancer, endometrial cancer | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT00000605 | Aug 1996 → Jul 2002 | coronary atherosclerosis, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00000419 | Apr 1996 → Aug 2002 | systemic lupus erythematosus | NYU Langone Health | Terminated | Met primary |
| Phase 3 | NCT00000601 | Jul 1995 → Jun 2000 | intermediate coronary syndrome | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00000559 | Mar 1995 → Aug 2001 | coronary artery disorder, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00319566 | Jul 1992 → Jul 2001 | coronary artery disorder | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT00000466 | Sep 1987 → Oct 2000 | coronary artery disorder, diabetes mellitus, hyperlipoproteinemia, hypertensive disorder +3 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00416429 | ? → Feb 2005 | kidney cancer | Centre Leon Berard | Completed | Missed primary |
| Phase 421 trials · 2 met primary · 2 missed | ||||||
| Phase 4 | NCT07462663 | Jan 2027 → Apr 2031 expected | atypical endometrial hyperplasia, endometrial cancer, intraepithelial neoplasia, morbid obesity | Hospital Universitari de Bellvitge | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06665997 | Jun 2025 → Jul 2028 expected | sickle cell disease | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 4 | NCT06637189 | Oct 2024 → Jun 2025 overdue | — | Ginefiv | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05651282 | Mar 2023 → Nov 2025 | endometrial cancer | University of British Columbia | Completed | No outcome recorded |
| Phase 4 | NCT05726903 | Dec 2022 → Nov 2023 | — | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT05491343 | Aug → Dec 2022 | arteriovenous hemangioma/malformation | HaEmek Medical Center, Israel | Unknown | No outcome recorded |
| Phase 4 | NCT04669678 | Nov 2021 → Feb 2024 | HIV infectious disease | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 4 | NCT04910711 | Oct 2021 → Aug 2023 | HIV infectious disease | Botswana Harvard AIDS Institute Partnership | Unknown | No outcome recorded |
| Phase 4 | NCT04654741 | Sep 2020 → Feb 2022 | infertility disorder | Casa di Cura Privata Villa Mafalda | Unknown | No outcome recorded |
| Phase 4 | NCT03844633 | Mar 2019 → May 2021 | — | Ohio State University | Terminated | Met primary Stop: Enrollment |
| Phase 4 | NCT02534688 | Jun 2015 → May 2016 | endometriosis | King Chulalongkorn Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02357368 | Feb 2015 → Oct 2019 | HIV infectious disease | Lisa Haddad | Completed | No outcome recorded |
| Phase 4 | NCT01966575 | Oct 2013 → Sep 2015 | infertility disorder, polycystic ovary syndrome | University of British Columbia | Withdrawn | No outcome recorded |
| Phase 4 | NCT01299116 | Dec 2011 → Jun 2016 | — | FHI 360 | Completed | No outcome recorded |
| Phase 4 | NCT01109979 | Dec 2009 → Jan 2012 | cardiovascular disorder | Brigham and Women's Hospital | Completed | Met primary |
| Phase 4 | NCT01148420 | Jan 2009 → Oct 2010 | uterine disorder | Women's Health Care Clinic, Torrance, California | Completed | No outcome recorded |
| Phase 4 | NCT01056042 | Jun 2007 → Apr 2011 | endometriosis | Prince of Songkla University | Completed | No outcome recorded |
| Phase 4 | NCT00294463 | Feb 2003 → Mar 2005 | osteoporosis | Erasmus Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00169299 | Jun 2001 → Sep 2004 | — | Kaiser Permanente | Unknown | Missed primary |
| Phase 4 | NCT00139685 | Apr 1998 → Aug 2006 | — | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00392093 | Nov 1997 → Dec 2001 | systemic lupus erythematosus | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Completed | Missed primary |
| Phase not applicable15 trials | ||||||
| — | NCT06549855 | Oct 2024 → Jul 2029 expected | endometrial cancer, endometrioid adenocarcinoma | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06468215 | Jul 2024 → Jul 2028 expected | endometrial endometrioid adenocarcinoma | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07488949 | Apr 2024 → Dec 2030 expected | chronic endometritis | Fang Wang | Recruiting | No outcome recorded |
| — | NCT05767086 | Mar 2023 → Sep 2024 | infertility disorder | Bezmialem Vakif University | Completed | No outcome recorded |
| — | NCT04710017 | Feb 2021 → Feb 2022 | uterine disorder | Assiut University | Completed | No outcome recorded |
| — | NCT05945407 | Aug 2016 → Dec 2023 overdue | endometrial cancer, endometrial endometrioid adenocarcinoma | Peking University People's Hospital | Recruiting | No outcome recorded |
| — | NCT02984696 | Mar 2015 → Oct 2016 | functional hypothalamic amenorrhea | Catholic University of the Sacred Heart | Unknown | No outcome recorded |
| — | NCT01578447 | Apr 2012 → Mar 2013 | — | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
| — | NCT01143207 | May 2010 → Oct 2011 | — | FHI 360 | Completed | No outcome recorded |
| — | NCT00668603 | Aug 2005 → Mar 2008 | cardiovascular disorder | University of Helsinki | Completed | No outcome recorded |
| — | NCT00350480 | Apr 2003 → Jun 2005 | menstrual disorder, uterine disorder | Kaiser Permanente | Completed | No outcome recorded |
| — | NCT00016601 | Jun 2001 → May 2004 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00061711 | Jul 2000 → Dec 2005 | — | National Institute on Aging (NIA) | Completed | No outcome recorded |
| — | NCT00006133 | Jun 2000 → ? | systemic lupus erythematosus | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| — | NCT00006324 | Dec 1999 → Dec 2002 | HIV infectious disease | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| Comparator or background therapy60 trials | ||||||
| Phase 0 | NCT05760144 Comparator | Jul 2023 → Nov 2026 expected | — | Oregon Health and Science University | Recruiting | No outcome recorded |
| Phase 0 | NCT03395756 Comparator | Aug 2018 → Oct 2020 | — | University of Southern California | Completed | No outcome recorded |
| Phase 0 | NCT03018249 Background | Oct 2017 → Apr 2018 | endometrial endometrioid adenocarcinoma | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 1 | NCT02792153 Background | Dec 2016 → Aug 2018 | anorexia nervosa | Johns Hopkins University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00543634 Comparator | Oct → Dec 2007 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00830414 Comparator | Apr → Sep 2002 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1/2 | NCT01791413 Comparator | Mar 2012 → Mar 2013 | endometriosis | Mahidol University | Completed | No outcome recorded |
| Phase 2 | NCT07714070 Background | Jul 2026 → Sep 2027 expected | atypical endometrial hyperplasia, endometrial cancer, progesterone resistance | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05247268 Comparator | Mar 2022 → Mar 2027 expected | endometrial carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT03689543 Background | May 2019 → Sep 2024 | — | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 2 | NCT03018366 Comparator | Jan 2017 → Feb 2023 | cardiovascular disorder, functional hypothalamic amenorrhea | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02228681 Comparator | May 2015 → Jan 2018 | endometrial cancer | GOG Foundation | Completed | No outcome recorded |
| Phase 2 | NCT02894151 Comparator | Apr 2015 → May 2016 | endometriosis | Chulalongkorn University | Completed | No outcome recorded |
| Phase 2 | NCT02064725 Background | Sep 2014 → Jan 2018 | endometrial carcinoma | Kevelt AS | Unknown | No outcome recorded |
| Phase 2 | NCT00807625 Comparator | Nov 2008 → Jul 2010 | HIV infectious disease | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT00739830 Comparator | Aug 2008 → Feb 2011 | endometrial cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00420342 Comparator | Jan 2007 → Sep 2008 | hypertensive disorder | Bayer | Completed | Missed primary |
| Phase 2 | NCT00437658 Comparator | Dec 2006 → Nov 2008 | endometriosis | AbbVie | Completed | Met primary |
| Phase 2 | NCT00302731 Comparator | Feb 2006 → Jan 2014 | premature menopause | Jeanne Drisko, MD, CNS, FACN | Terminated | No outcome recorded |
| Phase 2 | NCT00332553 Background | Feb 2002 → May 2004 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2/3 | NCT01472315 Comparator | Jan → Nov 2000 | sleep apnea syndrome | Turku University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT06904274 Comparator | Nov 2025 → Jun 2026 | endometrial hyperplasia without atypia | Bayer | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT06671548 Background | Jan 2024 → Nov 2026 expected | leiomyoma | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT02943655 Comparator | Nov 2017 → Oct 2020 | — | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT02732808 Background | Sep 2014 → Apr 2016 | female infertility | Royan Institute | Completed | No outcome recorded |
| Phase 3 | NCT02103764 Comparator | Aug 2013 → Jul 2018 | uterine disorder | Mahidol University | Unknown | Met primary |
| Phase 3 | NCT00808132 Comparator | Jan 2009 → Feb 2011 | osteoporosis | Pfizer | Completed | Met primary |
| Phase 3 | NCT00360490 Comparator | Jul 2006 → Jun 2008 | menstrual disorder | Bayer | Completed | Met primary |
| Phase 3 | NCT00745108 Comparator | Oct 2001 → Jul 2005 | — | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT03097120 Comparator | Jan 1995 → Jan 2001 | heart disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00004650 Background | Aug 1993 → ? | osteoporosis | National Institute of Dental and Craniofacial Research (NIDCR) | Completed | No outcome recorded |
| Phase 3 | NCT00191113 Background | Feb 1989 → Dec 2007 | Turner syndrome | Eli Lilly and Company | Completed | Met primary |
| Phase 4 | NCT04814927 Comparator | Mar 2021 → Dec 2022 | mucositis | Eastern Virginia Medical School | Completed | No outcome recorded |
| Phase 4 | NCT03309176 Comparator | Jun 2016 → Nov 2017 | anovulation | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02872818 Comparator | Oct 2014 → Mar 2015 | hyperplasia | Kayseri Education and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02103660 Comparator | Apr 2014 → Mar 2017 | HIV infectious disease | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT02340013 Comparator | Jul 2013 → Apr 2015 | female infertility | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01822288 Comparator | Nov 2012 → Jul 2021 | — | Far Eastern Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01776203 Comparator | Jan 2012 → Apr 2014 | uterine disorder | Kaiser Permanente | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01463202 Comparator | Nov 2011 → Feb 2017 | lactation disease, postpartum depression | Beatrice Chen | Completed | No outcome recorded |
| Phase 4 | NCT01698164 Comparator | Dec 2008 → Oct 2012 | breast cancer, cardiovascular disorder, osteoporosis, premature menopause | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01074892 Comparator | May 2005 → Dec 2013 | endometrial disorder | University Hospital of North Norway | Completed | No outcome recorded |
| Phase 4 | NCT00860964 Background | Feb 1998 → Feb 2003 | osteoporosis | Peking Union Medical College | Completed | No outcome recorded |
| — | NCT07732348 Comparator | Sep → Dec 2026 expected | female infertility, ovarian disorder | Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) | Not yet recruiting | No outcome recorded |
| — | NCT07032506 Background | May 2026 → Sep 2029 expected | adhesions of uterus | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| — | NCT07020429 Background | Sep 2025 → Jul 2030 expected | primary ovarian failure | Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting | No outcome recorded |
| — | NCT06304220 Comparator | Jul → Sep 2024 | female infertility | NextFertility | Unknown | No outcome recorded |
| — | NCT02855632 Background | Aug 2016 → Dec 2018 | adhesions of uterus | Sir Run Run Shaw Hospital | Unknown | Missed primary |
| — | NCT02550067 Comparator | Dec 2015 → Oct 2018 | HIV infectious disease | FHI 360 | Completed | No outcome recorded |
| — | NCT02293694 Comparator | Sep 2015 → Jan 2017 | — | FHI 360 | Completed | No outcome recorded |
| — | NCT01718444 Comparator | Mar 2015 → Jun 2016 | infertility disorder, polycystic ovary syndrome | University of Illinois at Chicago | Terminated | No outcome recorded |
| — | NCT02122198 Comparator | Sep 2014 → May 2017 | cardiovascular disorder, cognitive disorder | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT01418209 Comparator | Nov 2011 → Jan 2013 | — | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| — | NCT02144259 Comparator | Apr 2011 → Oct 2012 | — | University of Pennsylvania | Completed | No outcome recorded |
| — | NCT01191203 Comparator | Jul 2010 → Dec 2011 | HIV infectious disease | Emory University | Completed | No outcome recorded |
| — | NCT01019369 Comparator | Mar 2010 → Jan 2011 | — | Carolyn L. Westhoff | Completed | No outcome recorded |
| — | NCT00743574 Background | Aug 2008 → Feb 2013 | polycystic ovary syndrome, vitamin D deficiency | Yale University | Completed | No outcome recorded |
| — | NCT00563576 Background | Sep 2007 → Feb 2009 | hemometra | Columbia University | Completed | No outcome recorded |
| — | NCT00828542 Comparator | Jul 2007 → Feb 2008 | — | University of Sao Paulo | Completed | No outcome recorded |
| — | NCT01087593 Background | Aug 2001 → Oct 2007 | fibromyalgia | Ostergotland County Council, Sweden | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2023-07-03 | Impax Laboratories, LLC | Regulatory Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter amneal.com ↗
In addition, the Company announced it has received Abbreviated New Drug Application (ANDA) approvals from the U.S. Food and Drug Administration (“FDA”) for five complex generics products. |
| 2017-11-29 | Amphastar Pharmaceuticals, Inc. | Regulatory Amphastar Announces Approval for Medroxyprogesterone Acetate Injectable Suspension, USP amphastar.com ↗
We are excited about the approval of Medroxyprogesterone Acetate, which further expands the product offerings in our generic injectable portfolio and highlights our commitment and capability of bringing complex generic drugs to the market. |
| 2015-09-23 | Pfizer | Regulatory Pfizer’s Sayana® Press Becomes First Injectable Contraceptive In The United Kingdom Available For Administration By Self-Injection pfizer.com ↗
This follows the recent approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of an update to the Sayana® Press label, adding the option for self-injection by women when considered appropriate by a healthcare professional (HCP). |
| 2004-10-27 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approval Of Medroxyprogesterone Acetate Pre-Filled Syringe tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL pre-filled syringe. |
| 2004-07-29 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approval Of Medroxyprogesterone Acetate Injectable Suspension tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL in single-dose vials. |
All press releases naming this drug 7 releases
Evidence & citations 31 cited values
Every value below carries the sentence it was read from. 169 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | medroxyprogesterone acetate | “Study participants were 256 women who completed the Estrogen Replacement and Atherosclerosis (ERA) trial, a placebo-controlled, randomized trial that examined the effects of...” PMID 19155011 ↗ Dec 2008103“Daily administration of medroxyprogesterone acetate 10 mg (Progestrone®, 5mg bid; Aboureihan, Iran) is added beginning on stimulation day 12 for cases in which post-ovulation...” NCT02732808 ↗ “High-potency progestin given orally as background therapy in both groups: medroxyprogesterone acetate 250-500 mg/day or megestrol acetate 160-320 mg/day, with the specific...” NCT07714070 ↗ “2 weeks of oral estradiol (2 mg daily) or transdermal (two 0.1 mg patches changed twice weekly) estradiol supplementation followed by 1 week of oral or transdermal estradiol...” NCT07032506 ↗ “Clinical Efficacy and Pregnancy Outcomes of Doxycycline Combined With Medroxyprogesterone Acetate Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive...” NCT07488949 ↗ “OBJECTIVES: This study aimed to evaluate and compare local tolerability of investigational drug TV-46046 and reference drug Depo-subQ Provera 104, both containing...” PMID 37823034 ↗ Sep 2023 “Eligible patients will be enrolled into the study and administered sodium cridanimod (500 mg i.m./ twice a week) in combination with megestrol acetate (160 mg p.o./ day) or...” NCT02064725 ↗ “This study will compare the bioavailabity of three new investigational combination formulations of Premarin and medroxyprogesterone acetate (MPA) with a currently marketed...” NCT00401219 ↗ “To evaluate and compare Bone Mineral Density (BMD) in adolescent Depo-Provera Contraceptive Injection (DP150CI) users during depo medroxyprogesterone acetate (DMPA) therapy and...” NCT00139685 ↗ “The participants were treated in randomized order with either transdermal estradiol gel (1 mg), oral estradiol valerate (2 mg) with or without medroxyprogesterone acetate (5...” PMID 20443719 ↗ Oct 2010 “consisting of oestradiol valerate at a dose of 6 mg per day for 21-28 days with the addition of medroxyprogesterone acetate at a dose of 6 mg per day for the last 7-10 days of...” NCT02855632 ↗ |
| Known as | angonghuangtitong | “Patients in group A will orally take MPA (Medroxyprogesterone Acetate) (angonghuangtitong, Xianju pharmaceuticals, China)10mg daily from tenth day of menstruation for 15 days...” NCT03675139 ↗ |
| Known as | Cycrin | “1. Conjugated equine estrogens 0.625 mg/day plus 5 mg/day of medroxyprogesterone acetate p.o. for the first 10 days per-month (Premarin and Cycrin, respectively, Laboratorios Wyeth).” NCT00392093 ↗ |
| Known as | depo-medroxyprogesterone acetate | “DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide” NCT04669678 ↗1“150 mg Depo-Medroxyprogesterone Acetate administered every 13 weeks” NCT02103660 ↗ |
| Known as | depo-provera | “To evaluate and compare Bone Mineral Density (BMD) in adolescent Depo-Provera Contraceptive Injection (DP150CI) users during depo medroxyprogesterone acetate (DMPA) therapy and...” NCT00139685 ↗12“Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ...” NCT01299116 ↗ “Patients receive medroxyprogesterone acetate suspension (Depo- Provera) intramuscularly once monthly for 3 months (days 1, 31, and 62).” NCT00003179 ↗ “Millions of women around the world use depot medroxyprogesterone acetate (DMPA, trade name Depo-Provera) for prevention of pregnancy.” NCT02412436 ↗ “Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women” NCT00016601 ↗ “using an injectable contraception, Depot Medroxyprogesterone Acetate (Depo-Provera), can reduce the pain” NCT06665997 ↗ “subcutaneous depot medroxyprogesterone acetate (DMPA-SC; also known as depo-provera)” NCT00437658 ↗ “Depot medroxyprogesterone acetate (DMPA) is a generic form of the DepoProvera® shot.” NCT01461824 ↗ “Depo-medroxyprogesterone acetate (DMPA) also called Depo-Provera” NCT05760144 ↗ “who want to use DMPA (Depo-Provera; Pfizer Corp.)” NCT03844633 ↗ “MedroxyPROGESTERone Injection [Depo-Provera]” NCT05491343 ↗ |
| Known as | Depo-SubQ Provera 104 | “Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ...” NCT01299116 ↗ |
| Known as | DepoProvera, depot medroxyprogesterone acetate (DMPA) | “DepoProvera, depot medroxyprogesterone acetate (DMPA)” NCT02144259 ↗ |
| Known as | Depot medroxyprogesterone acetate | “Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ...” NCT01299116 ↗14“The objective of this study is to explore the potential of depot medroxyprogesterone acetate (DMPA) given as a 150-mg intramuscular injection for use as an emergency contraceptive.” NCT03395756 ↗ “Sayana® Press is a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in a prefilled, auto-disabled injection system called Uniject (Pfizer, Inc., USA).” NCT02293694 ↗ “one dose of Depot medroxyprogesterone acetate (DMPA) 150mg will be administered to each participant as an intramuscular injection” NCT03197961 ↗ “Depot medroxyprogesterone acetate, brand name Depo Provera 150mg/ml, injected intramuscularly, every month for 3 months” NCT06145438 ↗ “DMPA is an intramuscular injection of 150mg of depot medroxyprogesterone acetate.” NCT02144259 ↗ “DMPA (depot medroxyprogesterone acetate or the 'depot' injection)” NCT01231451 ↗ |
| Known as | depot medroxyprogesterone acetate (DMPA) | “depot medroxyprogesterone acetate (DMPA)” NCT02293694 ↗ |
| Known as | Depot MPA | “For the patients in the Depot MPA Group, 150 mg depot MPA was given intramuscularly once every three months.” NCT02894151 ↗ |
| Known as | Depot-Medroxyprogestereone Acetate | “Drug: Depot-Medroxyprogestereone Acetate” NCT03395756 ↗ |
| Known as | DMPA | “Forty healthy women exclusively breastfeeding were randomized to receive either ETG-releasing implant 24-48 h after delivery (n=20) or depot medroxyprogesterone acetate (DMPA...” PMID 19913145 ↗ Jul 200916“To evaluate and compare Bone Mineral Density (BMD) in adolescent Depo-Provera Contraceptive Injection (DP150CI) users during depo medroxyprogesterone acetate (DMPA) therapy and...” NCT00139685 ↗ “Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ...” NCT01299116 ↗ “Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients” NCT02534688 ↗ “Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients” NCT02894151 ↗ “The objective of this study is to explore the potential of depot medroxyprogesterone acetate (DMPA) given as a 150-mg intramuscular injection for use as an emergency contraceptive.” NCT03395756 ↗ “Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment.” NCT02550067 ↗ “OBJECTIVES: We evaluated the effect of immediate postpartum use of depot medroxyprogesterone acetate (DMPA) on the timing of lactogenesis stage II (LS-II).” PMID 39424123 ↗ Oct 2024 “Sayana Press (SP), a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) prefilled in a Uniject injection system” PMID 24332432 ↗ Nov 2013 “one dose of Depot medroxyprogesterone acetate (DMPA) 150mg will be administered to each participant as an intramuscular injection” NCT03197961 ↗ “DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide” NCT04669678 ↗ |
| Known as | DMPA-IM | “We assessed acceptability of SP versus intramuscular DMPA (DMPA-IM) among HIV-positive women and their care providers in Rakai, Uganda.” PMID 24332432 ↗ Nov 2013 |
| Known as | DMPA-SC | “subcutaneous depot medroxyprogesterone acetate (DMPA-SC; also known as depo-provera)” NCT00437658 ↗ |
| Known as | DP150CI | “To evaluate and compare Bone Mineral Density (BMD) in adolescent Depo-Provera Contraceptive Injection (DP150CI) users during depo medroxyprogesterone acetate (DMPA) therapy and...” NCT00139685 ↗ |
| Known as | Farlutal | “Patients will receive medroxyprogesterone acetate ("FARLUTAL") 250-500mg/d or megestrol acetate” NCT05945407 ↗1“General Name/Brand name:Farlutal tab. 500mg/ Pfizer” NCT03567655 ↗ |
| Known as | medroxy progesterone | “In this clinical trial, it is decided that 30 patients who are candidates for photorefractive keratectomy will receive a drop of prepared medroxyprogesterone randomly in one of...” NCT05973253 ↗35“Subjects with rest angina and no contraindications to hormone therapy were randomized to receive intravenous followed by oral conjugated estrogen for 21 days, intravenous...” NCT00000601 ↗ “The purpose of the study is to compare the pharmacokinetics and relative bioavailability of medroxyprogesterone in healthy female participants following subcutaneous injection...” NCT04893798 ↗ “Progesterone is a peanut based product and for patients with a peanut allergy we will replace this with a synthetic progestin at an equivalent dose, medroxyprogesterone 10mg.” NCT03018366 ↗ “Transdermal administration(50 ug daily)for a period of ten weeks with additional treatment of medroxyprogesterone (10mg daily) for the last two weeks” NCT01087593 ↗ “22 AN girls were randomized to transdermal estradiol (plus cyclic medroxyprogesterone) or placebo in a double-blind study for 12 months.” PMID 22728230 ↗ Jun 2012 “The 8 week estradiol treatment is followed by 14 days (2 weeks) of progesterone taper (as medroxy-progesterone 10 mg/day).” NCT01418209 ↗ “oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger” NCT04414761 ↗ “they will be prescribed medroxyprogesterone (Provera) 10 mg per day for first 12 calendar days of each month” NCT02922348 ↗ “estradiol valerate 1mg/d,medroxyprogesterone 6mg/d for 10 days,calcium 900mg/d, VitD200iu/d and exercise” NCT00860964 ↗ “eyes that received one drop of medroxy progesterone at the end of the photorefractive keratectomy(PRK)” NCT05973253 ↗ |
| Known as | medroxy progestrone acetat | “prepared drop of medroxy progestrone acetat 1%” NCT05973253 ↗ |
| Known as | Medroxyprogesterone 17-Acetate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01776203 ↗ |
| Known as | medroxyprogesterone acetate (MPA) | “medroxyprogesterone acetate (MPA)” NCT03463252 ↗ |
| Known as | medroxyprogesterone acetate (MPA), i.e. Provera | “medroxyprogesterone acetate (MPA), i.e. Provera” NCT01966575 ↗ |
| Known as | Meishiya | “Medroxyprogesterone acetate oral suspension (Meishiya®) (administered from Day 1 to 21, 5 ml, once daily)” NCT07124195 ↗ |
| Known as | MPA | “Patients with histologically confirmed grade 1 endometrioid adenocarcinoma with superficial myometrial invasion or patients with histologically confirmed grade 2 endometrioid...” NCT03567655 ↗32“Study participants were 256 women who completed the Estrogen Replacement and Atherosclerosis (ERA) trial, a placebo-controlled, randomized trial that examined the effects of...” PMID 19155011 ↗ Dec 2008 “OBJECTIVES: This study aimed to evaluate and compare local tolerability of investigational drug TV-46046 and reference drug Depo-subQ Provera 104, both containing...” PMID 37823034 ↗ Sep 2023 “This study will compare the bioavailabity of three new investigational combination formulations of Premarin and medroxyprogesterone acetate (MPA) with a currently marketed...” NCT00401219 ↗ “OBJECTIVE: To compare medroxyprogesterone acetate (MPA) concentrations between HIV-positive women on antiretroviral therapy (ART) and HIV-negative women initiating depot...” PMID 31374188 ↗ Jul 2019 “Progestins (like medroxyprogesterone acetate, MPA) are female hormones and act through progesterone receptors, so it would be likely women to have less side effects from MPA...” NCT01472315 ↗ “Patients in group A will orally take MPA (Medroxyprogesterone Acetate) (angonghuangtitong, Xianju pharmaceuticals, China)10mg daily from tenth day of menstruation for 15 days...” NCT03675139 ↗ “Common HT for menopausal syndrome with intact uterus includes tibolone, estradiol valerate (E2V) 1mg \& medroxyprogesterone acetate (MPA) 2.5 mg, and conjugated equine estrogens \& MPA.” NCT01822288 ↗ “Eligible patients will be randomly assigned in a two-by-two factorial design to either medroxyprogesterone (MPA), subcutaneous IFN, subcutaneous IL2, or a combination of IFN and IL2.” NCT00291369 ↗ “Injection Cyclofem contains 25 mg medroxyprogesterone acetate (MPA) and 5 mg estradiol cypionate as a microcrystalline suspension in 0.5ml aqueous solution and is supplied in vials.” NCT01699022 ↗ “This current trial compared a single intramuscular dose of medroxyprogesterone acetate (MPA), depot preparation, versus daily oral venlafaxine as treatment for hot flashes.” PMID 16505409 ↗ Feb 2006 |
| Known as | progest | “medroxyprogesterone acetate (progest)” NCT02943655 ↗ |
| Known as | Progestrone | “Daily administration of medroxyprogesterone acetate 10 mg (Progestrone®, 5mg bid; Aboureihan, Iran) is added beginning on stimulation day 12 for cases in which post-ovulation...” NCT02732808 ↗ |
| Known as | Provera | “Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.” NCT00360490 ↗6“Patients receive oral medroxyprogesterone acetate (Provera) once daily for 3 months.” NCT00003179 ↗ “medroxyprogesterone acetate (MPA, Provera)” NCT00350480 ↗ “Medroxyprogesterone (Provera)” NCT00743574 ↗ |
| Known as | Sayana Press | “SC MPA or Sayana® Press is a single-dose container with 104 mg medroxyprogesterone acetate (MPA) in 0.65 mL suspension for injection.” NCT04669678 ↗1“Sayana Press (SP), a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) prefilled in a Uniject injection system” PMID 24332432 ↗ Nov 2013 |
| Known as | TV-46046 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04682353 ↗ |
| Action | Inhibit | “The putative role of the progestin is to reduce the responsiveness of the endometrium to estradiol by downregulating endometrial estrogen receptors.” NCT01776203 ↗ |
| Modality | Other / unclassified | “Medroxyprogesterone acetate is a synthetic progestin” NCT06637189 ↗ |
| Route | Oral | “Patients receive oral medroxyprogesterone acetate on days 1-14.” NCT00002920 ↗ |